市場調查報告書
商品編碼
1245691
全球心血管數字解決方案市場規模、份額、行業趨勢分析報告,按服務類型、最終用途、部署(基於雲、本地)、組件(設備、軟件)、地區展望和預測,2022-2028 年Global Cardiovascular Digital Solutions Market Size, Share & Industry Trends Analysis Report By Service Type, By End-use, By Deployment (Cloud-Based and On-premise), By Components (Devices and Software), By Regional Outlook and Forecast, 2022 - 2028 |
心血管數字解決方案的全球市場規模預計在預測期內以 4.8% 的複合年增長率增長,到 2028 年達到 1281 億美元。
不適當或不正確的飲食、缺乏運動、吸煙和過量飲酒是心血管疾病(包括心髒病和中風)的最大行為風險因素。 血壓升高、血糖升高、血脂升高以及超重和肥胖也可能是人們行為危險因素的症狀。 在初級保健環境中,可以評估這些“中間危險因素”,並表明心髒病發作、中風和心力衰竭等並發症的風險增加。
CVD 還有其他潛在原因。 它們反映了推動社會、經濟和文化變革的三大力量:城市化、人口老齡化和全球化。 遺傳因素、壓力和貧困也是 CVD 的預測因素。 還需要針對高血壓、糖尿病和血脂過高的藥物治療,以降低患有這些疾病的人的心血管風險並阻止中風和心髒病發作。
COVID-19 影響分析
對於症狀較輕的患者,在線諮詢是強制性的社會疏遠措施。 此外,我們還能夠減輕已經因 COVID-19 病例數量而負擔過重的醫院的負擔。 醫療物聯網設備的發展也使患者能夠充分利用門診就診並減少複診次數。 這些設備也可以在緊急情況下使用。 此外,大流行期間遇到的資源稀缺導致了基於競爭價值的定價模型的發展。 因此,大流行對市場產生了積極影響。
市場增長因素
尖端治療的使用增加
隨著新的心血管治療方案的開發以及 TAVR 和 3D 打印等尖端治療技術的採用,MedTech CVD 行業正在不斷發展。 醫療機構正在尋找可用於管理患者旅程的範圍廣泛的治療、診斷和監測解決方案。 這些解決方案必須由正確的技術提供支持,以研究和引人注目的價值主張為後盾,並在正確的時間提供。 這將推動未來幾年心血管數字解決方案市場的增長。
提供者和醫療服務的轉變
越來越多的證據表明,某些 CVD 干預措施,尤其是數字工具,對患者和醫生都有好處。 例如,針對患者的數字健康干預可能會減少看醫生的次數,因為設備可以通過遠程連接收集數據。 此外,醫療保健專業人員可以將數字解決方案用作臨床決策支持工具,以輸入患者數據並提出治療建議。 因此,醫療保健提供方式的變化和醫療保健工作者的可用性已經實現了技術的使用,可以在更短的時間內為更多的患者提供服務,從而增強了市場的增長前景。
市場約束
臨床試驗人員不足
根據臨床研究協會聯合會的數據,臨床試驗工作者 (CTA) 和臨床研究工作者 (CRA) 的需求特別高。 不幸的是,在過去的十年中,製造商和 CRO 都沒有對他們的畢業生進行充分的培訓,從而加劇了這個問題。 以滿足該行業的研究需求。 這種人才缺口阻礙了創新技術的採用,並可能在未來幾年對心血管數字解決方案市場產生不利影響。
服務類型展望
根據服務類型,心血管數字解決方案市場分為無創檢測、CVD 健康信息學、心臟康復計劃等。 2021 年,無創檢測部門將在心血管數字解決方案市場中佔據最高的收入份額。 已經引入非侵入式監測技術來收集干擾人日常生活的生理信號和特徵,例如心率、心電圖、血壓和血糖水平。 此外,最近在謹慎和無線通信技術方面的進步使得能夠從遠程位置實時收集現場生理數據。
組件視角
心血管數字解決方案市場基於組件細分為設備和軟件。 2021 年,軟件部門在心血管數字解決方案市場中佔據了重要的收入份額。 心血管健康是衡量患者從慢性心髒病康復進展的重要指標。 因此,監測心血管健康已成為治療策略不可或缺的一部分,推動了對軟件解決方案的需求。 心髒病專家和診所工作人員可以使用技術突破和最新的軟件更新輕鬆地對患者進行心臟測試。
發展前景
根據部署,心血管數字解決方案市場分為基於雲的和本地的。 2021 年,基於雲的細分市場在心血管數字解決方案市場中的收入份額最大。 為了擺脫預算限制,醫療保健行業需要加強資源並開發有效的方法來減少支出。 因此,醫療保健組織和醫院對基於雲的解決方案的採用正在增加。 基於雲的解決方案已經成為必須為醫療保健組織購買和擁有所有技術的傳統戰略的替代方案。
最終用戶展望
按最終用戶劃分,心血管數字解決方案市場分為醫院和診所、門診護理中心等。 2021 年,門診護理中心部分在心血管數字解決方案市場中佔據了相當大的收入份額。 各種情況都需要使用動態心臟監測服務,例如 MCOT(移動心臟門診遙測)。 為了持續監測心臟活動並提供所需信息,可以實時診斷出院後經導管主動脈瓣置換術 (TAVR) 患者可能發生的臨床嚴重心律失常。
區域展望
按地區劃分,分析了北美、歐洲、亞太地區和 LAMEA 的心血管數字解決方案市場。 2021 年,亞太地區心血管數字解決方案市場出現大幅增長。 這一區域市場的擴張是由亞洲國家日益老齡化的人口和心臟健康管理系統的進步推動的。 然而,亞太地區是人口密度最高、文化、社會經濟水平、種族和衛生保健系統最廣泛的地區,因此在心血管疾病的預防和治療方面面臨一些挑戰。
市場進入者採取的主要策略是根據基數矩陣中的分析引入產品。 Apple, Inc. 和 Verily Life Sciences LLC 是心血管數字解決方案市場的先驅。 eviCore Healthcare、Koninklijke Philips N.V.和 Bardy Diagnostics, Inc. 等公司是心血管數字解決方案市場的領先創新者。
The Global Cardiovascular Digital Solutions Market size is expected to reach $128.1 billion by 2028, rising at a market growth of 4.8% CAGR during the forecast period.
Cardiovascular digital solutions are the fusion and application of digital technologies like software, sensors, wearables, smartphones, artificial intelligence, and virtual healthcare solutions. In order to develop and offer effective healthcare solutions, digital healthcare solutions are being used. The most frequent cause of morbidity and mortality, cardiovascular (CVD) illnesses, necessitates a comprehensive multi-parameter examination beyond the ECG.
For the early detection, monitoring, and treatment of cardiac problems, digital solutions are crucial. This allows for more specialized and effective cardiac care. One of the main reasons propelling the expansion of the cardiovascular digital solutions market is the rise in the prevalence of cardiovascular disorders worldwide, as well as the quickening pace of healthcare technology internationally.
Inadequate or wrong food intake, inactivity, use of tobacco, and excessive alcohol consumption are the biggest behavioral risk factors for cardiovascular diseases like heart disease and stroke. In addition, raised blood pressure, elevated blood glucose, elevated blood lipids, as well as being overweight, and obesity might be symptoms of behavioral risk factors in people. In primary care settings, these "intermediate risk factors" can be assessed and show a higher risk of complications like heart attack, stroke, and heart failure.
There are other additional underlying causes of CVDs. These reflect the three main forces that are causing social, economic, and cultural change: urbanization, population aging, and globalization. Hereditary factors, stress, and poverty are other CVD predictors. In order to lower cardiovascular risk and stop strokes and heart attacks in persons with these illnesses, the pharmacological treatment for hypertension, diabetes, and excessive blood lipids is also required.
COVID-19 Impact Analysis
Patients with mild symptoms were required to consult online as part of the social distancing procedures. Additionally, it eased the strain on hospitals already overburdened with COVID-19 patient counts. The development of Medical IoT devices also helped patients maximize outpatient care and reduce follow-up visits. These devices could also be employed in an emergency. Additionally, the resource shortage encountered during the pandemic led to the development of value-based and competitive pricing models. Therefore, the pandemic had a favorable impact on the market.
Market Growth Factors
Rising use of cutting-edge treatment methods
New cardiovascular therapy alternatives are being developed, and the MedTech CVD industry is growing, owing to the adoption of cutting-edge treatment technologies like TAVR and 3D printing. Providers are looking for a wide range of therapeutic, diagnostic, and monitoring solutions that they can use to manage the patient journey. These solutions should be empowered by the right technology, backed by research and a compelling value proposition, and made available at the appropriate time. This will propel the growth of the cardiovascular digital solutions market in the coming years.
Shifts in providers and healthcare delivery methods
There is mounting evidence that certain CVD initiatives centered on digital tools have benefited patients and physicians alike. For example, since devices may collect data via remote connectivity, digital health interventions for patients may result in fewer doctor visits. Furthermore, digital solutions can be used as clinical decision-support tools by healthcare professionals who input patient data to produce therapy suggestions. Hence, the changing methods of healthcare delivery and availability of healthcare providers have substantiated the use of technology to cater to more patients in a shorter time, which has also boosted the growth prospects for the market.
Market Restraining Factors
Insufficiently qualified staff for clinical trials
According to the Association of Clinical Research Organizations, there is a particularly great need for clinical trial associates (CTA) and clinical research associates (CRA). Unfortunately, over the past ten years, the problem has worsened because neither manufacturers nor CROs has provided graduates with enough skill training to meet the needs of the industry's research. This talent gap may hinder the adoption of innovative techniques and technology, which may have an adverse effect on the market for cardiovascular digital solutions in the years to come.
Service Type Outlook
Based on service type, the cardiovascular digital solutions market is categorized into unobtrusive testing, CVD health informatics, cardiac rehab programs, and others. The unobtrusive testing segment garnered the highest revenue share in the cardiovascular digital solutions market in 2021. Unobtrusive monitoring techniques are being deployed to collect physiological signals and characteristics that interfere with a person's daily life, like heart rate, ECG, blood pressure, and blood glucose. In addition, modern advances in inconspicuous and wireless communication technologies enable real-time on-site physiological data collection from remote sites.
Component Outlook
On the basis of components, the cardiovascular digital solutions market is divided into devices and software. The software segment recorded a significant revenue share in the cardiovascular digital solutions market in 2021. An essential marker of a patient's progress in recovering from chronic cardiac diseases is cardiovascular health. Therefore, monitoring cardiovascular health has become an integral part of the therapy strategy, which has increased the demand for software solutions. Cardiologists and clinic staff can easily do cardiac testing with patients using technological breakthroughs and the latest software updates.
Deployment Outlook
Based on deployment, the cardiovascular digital solutions market is segmented into cloud-based and on-premise. The cloud-based segment witnessed the maximum revenue share in the cardiovascular digital solutions market in 2021. To stay within budgetary restrictions, the healthcare industry needs to develop efficient ways to enhance its resources and decrease spending. Therefore, the adoption of cloud-based solutions by healthcare organizations and hospitals has increased. Cloud-based solutions have emerged as a substitute for the conventional strategy, in which institutions must buy and own all the technology.
End-Use Outlook
On the basis of end-use, the cardiovascular digital solutions market is segmented into hospitals & clinics, ambulatory care centers, and others. The ambulatory care centers segment acquired a substantial revenue share in the cardiovascular digital solutions market in 2021. Various circumstances call for using ambulatory cardiac monitoring services like MCOT (Mobile Cardiac Outpatient Telemetry). As it continually monitors heart activity and provides essential information, it enables real-time diagnosis of clinically severe arrhythmias that may arise in transcatheter aortic valve replacement (TAVR) patients after discharge.
Regional Outlook
Based on region, the cardiovascular digital solutions market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The Asia Pacific region witnessed a considerable growth rate in the cardiovascular digital solutions market in 2021. The expansion of the regional market is being driven by the rise in the elderly population and the advancement of heart health management systems in Asian nations. However, Asia Pacific presents several difficulties in the prevention and treatment of cardiovascular disease as the region with the biggest density of population and the greatest range of cultures, socioeconomic levels, ethnicities, and healthcare systems.
The major strategies followed by the market participants are Product Launches Based on the Analysis presented in the Cardinal matrix; Apple, Inc. and Verily Life Sciences LLC are the forerunners in the Cardiovascular Digital Solutions Market. Companies such as eviCore Healthcare, Koninklijke Philips N.V. and Bardy Diagnostics, Inc., are some of the key innovators in Cardiovascular Digital Solutions Market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Apple, Inc., General Electric Company, Koninklijke Philips N.V., Verily Life Sciences LLC (Alphabet, Inc.), iRhythm Technologies, Inc., Bardy Diagnostics, Inc. (Hill-Rom Holdings Inc) (Baxter International Inc.), eviCore Healthcare (Express Scripts Holding Company) (Cigna Corporation), AliveCor, Inc., Cardiotrack, and HeartFlow, Inc.
Recent Strategies Deployed in Cardiovascular Digital Solutions Market
Mergers & Acquisition
Jan-2023: GE HealthCare took over IMACTIS, an innovator in the rapidly growing field of computed tomography (CT) interventional guidance across an array of care areas. Through this acquisition, GE Healthcare would be able to strengthen its recommendation offering for customers and patients.
Nov-2021: Koninklijke Philips N.V. acquired Cardiologs, a France-based medical technology company focused on transforming cardiac diagnostics using artificial intelligence (AI) and cloud technology. Through his acquisition, Koninklijke Philips N.V. would be able to strengthen its diagnostics offering and cardiac monitoring with electrocardiogram (ECG) analysis, creative software technology, and reporting services.
Feb-2021: Koninklijke Philips N.V. took over BioTelemetry, Inc., a leading U.S.-based provider of remote cardiac diagnostics and monitoring. Through this acquisition, Koninklijke Philips N.V. would be in a favorable position to enhance patient care across care environments for medical conditions and numerous diseases with the help of the combination of both organization's portfolio and service platforms.
Product Launch and Product Expansions
Nov-2022: Verily Life Sciences LLC launched Primasun. Primasun is a digital health joint venture between Verily Life Sciences LLC and ResMed Inc. Moreover, Primasun would integrate advanced healthcare research and technology into one complete digital health platform.
Sep-2022: GE Healthcare unveiled Optima IGS 320. The Optima IGS 320 is a made in India', 'AI-powered' Cath lab product. Additionally, the Cath lab advances the GE proprietary AutoRight technology where AutoRight comes with Artificial Intelligence that automatically optimizes dose and image parameters in real-time allowing clinicians to concentrate their expertise and attention on patients.
May-2022: AliveCor unveiled the KardiaComplete. The new product KardiaComplete is a complete heart health industry solution created to lower the cost of cardiac care and improved health outcomes. Additionally, this new product would be open for people diagnosed with arrhythmias and hypertension.
Nov-2021: Koninklijke Philips N.V. unveiled the new AI-enabled innovations in MR imaging. The new MR portfolio of intelligent combined solutions is created to fasten up and streamline workflows, and MR exams, optimize diagnostic quality, and aid secure the sustainability and efficiency of radiology operations.
Jan-2020: Bardy Diagnostics, Inc. unveiled the Carnation Ambulatory Monitor. The Carnation Ambulatory Monitor is the industry's only P-wave-centric arrhythmia detection device and ambulatory cardiac patch monitor. Additionally, Bardy Diagnostics, Inc. is delighted to create precise and state-of-the-art cardiac monitoring technologies that allow fresh opportunities to redefine and reimagine patient care.
Aug-2018: Koninklijke Philips N.V. unveiled the EPIQ CVx. The EPIQ CVx is the new cardiovascular ultrasound system developed on a strong EPIQ ultrasound platform. Additionally, EPIQ CVx is specially crafted to improve diagnostic confidence and streamline workflow for clinicians.
Partnerships, Collaborations & Agreements
Jan-2023: Koninklijke Philips N.V. expanded its partnership with Masimo, a global medical technology company. Under this partnership, Koninklijke Philips N.V. would boost patient monitoring abilities in-home telehealth applications with the Masimo W1™ advanced health tracking watch. Moreover, the W1 would combine with Philips's enterprise patient monitoring ecosystem to extend the forefront of telehealth and telemonitoring.
Oct-2022: GE Healthcare came into collaboration with Tribun Health, a pioneer in digital pathology workflow solutions. Under this collaboration, both organizations committed to delivering digital pathology departmental solutions that provide healthcare providers with a more comprehensive idea of patient records. Moreover, GE Healthcare would present a data management solution by combining Tribun's Health Suite data into GE Healthcare's solution.
Sep-2022: AliveCor partnered with Biotronik SE & Co KG, a leading medical device company. Under this partnership, AliveCor would integrate its FDA-cleared ECG technology with BIOTRONIK's implantable devices for cardiac rhythm diagnostics. Moreover, this would further enable a comprehensive picture of the patient's heart health while delivering essential understandings for physicians.
Mar-2022: GE Healthcare came into partnership with AliveCor, a company that is transforming cardiological care using deep learning. Under this partnership, GE Healthcare's MUSE Cardiac Management System would be integrated with the AliveCor KardiaMobile 6L ECG device. Moreover, medical-grade six-lead electrocardiograms (ECGs) taken by patients on an AliveCor KardiaMobile 6L ECG device outside of the hospital setting would be transferred to GE Healthcare's MUSE Cardiac Management System for physicians to view and evaluate.
Jan-2018: GE Healthcare came into collaboration with F. Hoffmann-La Roche AG, a Swiss multinational healthcare company that operates worldwide. Under this collaboration, GE Healthcare would co-market and co-develop digital clinical decision-support solutions to enhance therapy for critical care and oncology patients. Moreover, this collaboration would help GE Healthcare to fasten the delivery of data-driven precision health for patients, customers, and the healthcare industry.
Market Segments covered in the Report:
By Service Type
By End-use
By Deployment
By Components
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures